Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U03 Substudy 03A in first-line advanced clear cell renal cell carcinoma
NL-OMON56282Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab, quavonlimab, vibostolimab, lenvatinib and belzutifan in clear cell renal cell carcinoma (ccRCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events and 2 more. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON56282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56282.